Where this fits: The same medication classes have dominated anxiety treatment for three decades. This lesson covers what is genuinely new: psychedelic-assisted therapy (the MDMA and psilocybin data), ketamine and esketamine, novel molecular targets and why promising science fails in clinical trials, D-cycloserine augmentation of exposure therapy, and the CBD and cannabis evidence your patients are already asking about.